Primary aldosteronism (PA), first described by Jerome W. Conn in 1955 [1], is characterized
by excessive, autonomous aldosterone production relative to suppressed plasma renin. PA …

After discussing in Part I (Rossi et al, J Nephrol. 2008; 21: 447-454) the screening strategy to
identify the hypertensive patients with primary aldosteronism (PA), we report here an update …

Numerous studies conducted in recent years have reported an increase in the prevalence of
primary aldosteronism (PA). This increase has arisen because of changes in our screening …

Primary aldosteronism (PA), characterized by inappropriately high concentrations of the
adrenal derived hormone aldosterone, is the most common endocrine cause of arterial …

Primary aldosteronism (PA) comprises two main subtypes: unilateral aldosteronism, mainly
caused by aldosterone-producing adenoma; and bilateral adrenal hyperplasia. Establishing …

Primary aldosteronism (PA) has a prevalence in the general hypertensive population from 5
to 10%, and is widely recognized as the most frequent form of secondary hypertension. The …

Objective: With the increased emphasis on personalized and individualized medicine, the
American Association of Clinical Endocrinologists Adrenal Scientific Committee has …

In this issue of the JCEM, Kupers et al.(1) make a truly groundbreaking contribution to the
management of primary aldosteronism (PA). In a retrospective study on consecutive patients …

Hypertension is a leading risk factor for death and disability globally; a significant proportion
of hypertension is caused by primary aldosteronism (PA, also known as Conn syndrome) …

Unilateral primary aldosteronism (PA) is often treated with adrenalectomy, but hypertension
resolution rates are variable. A valid estimate of the postoperative normotension rate is …